 Ovid Therapeutics NASDAQ:OVIDs stock had its buy rating reissued by stock analysts at William Blair in a note issued to investors on Friday, AnalystRatings.com reports. William Blair also issued estimates for Ovid Therapeutics Q1 2021 earnings at 0.31 EPS, Q2 2021 earnings at 0.32 EPS, Q3 2021 earnings at 0.29 EPS, Q4 2021 earnings at ... 